Long-term outcome was analyzed in 28 patients transplanted between 1989 and 1992 following busulfan and cyclophosphamide and who had busulfan levels studied. While there was no significant correlation of busulfan levels with diagnosis, patients who had received extensive prior chemotherapy had a significantly higher area under the curve (AUC; P = 0.02) and maximum busulfan levels (Cmax; P = 0.03). High AUC was associated with the development of hepatic veno-occlusive disease (P = 0.03) and with early transplant-related mortality (P = 0.06). No significant correlation of busulfan levels with relapse, late non-relapse death, late complications, nor event-free survival was detected. Bone Marrow Transplantation (2001) 27, 1121-1124.
Busulfan is a crucial component of commonly used preparative regimens for autologous and allogeneic hematopoietic stem cell transplantation. [1] [2] [3] [4] [5] Plasma concentrations following oral administration of busulfan vary considerably from patient to patient. High plasma levels have been associated with increased acute toxicity [6] [7] [8] and low levels with allograft rejection and relapse. 8, 9 No such studies with longterm follow-up have been published. The purposes of this study were to determine whether pretransplant factors influence busulfan pharmacokinetics, to study the effect of busulfan levels on transplant-related toxicity and mortality, and to determine whether prolonged follow-up would demonstrate a significant correlation of busulfan levels with survival and delayed complications. 
Materials and methods

Patient Characteristics
Between 1989 and 1992, 28 patients aged 4 to 54 with myelodysplastic syndrome (MDS)/acute leukemia (n = 10), chronic myelogenous leukemia in chronic (n = 9), or accelerated (n = 2) phase, non-Hodgkin's lymphoma (n = 5) or Hodgkin's disease (n = 2) underwent hematopoietic progenitor cell transplantation and had busulfan levels studied. Patient characteristics are described in Table 1 . The protocol was approved by the institutional review board and informed consent was obtained from each patient. All patients entered on the protocol are presented. Results have not been previously published.
Treatment regimen
All patients received a regimen of busulfan 1 mg/kg administered orally every 6 h for 4 successive days, followed by cyclophosphamide 60 mg/kg administered intravenously on each of 2 successive days as previously described. 2 Busulfan was administered as 2 mg tablets in gelatin capsules. All patients received phenytoin at a loading dose of 15 mg/kg and daily maintenance from 300 mg to 500 mg, based on plasma levels, for 5 days. Six patients (all with Hodgkin's or non-Hodgkin's lymphoma) underwent autologous bone marrow transplantation; 22 underwent allogeneic marrow transplantation, 16 from matched sibling donors, two from one or two antigen mismatched family members, and four from matched unrelated donors. Prophylaxis against GVHD consisted of either methylprednisolone and cyclosporine or methotrexate and cyclosporine.
Pharmacokinetic studies
The HPLC method used in pharmacokinetic analyses was previously described. 10 Busulfan levels were collected 0, 0.5, 1, 2, 4, and 6 h following the fifth and 13th doses of busulfan.
Regimen-related toxicity
Hepatic veno-occlusive (VOD) was defined and graded according to previously described criteria. 11 Regimenrelated toxicity was scored according to Bearman et al. UPN = unique patient number; BMT = bone marrow transplant; MATS = HLA-matched sibling; MIS2P = 2 antigen mismatched parent; MIS1S = 1 antigen mismatched sibling; Auto = autologous; MUD = matched unrelated donor; AML = acute myelocytic leukemia; CML = chronic myelogenous leukemia; ALL = acute lymphoblastic leukemia; NHL = non-Hodgkin's lymphoma; HOD = Hodgkin's disease; MDS = myelodysplastic syndrome; REM1 = first remission; B = blastic phase; A = accelerated phase; REM2 = second remission; REL2 = second relapse; REL1 = first relapse; REL3 = third relapse; REF = refractory; PR3 = third partial remission; PR4 = fourth partial remission; C2 = second chronic phase.
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Late complications
Chronic GVHD 13 and obstructive bronchiolitis 14 were defined according to previously published criteria.
Statistical analysis
The Mann-Whitney U test 15 and the Kruskal-Wallis test 16 were utilized to examine the relationship between busulfan concentrations and several variables. 5 As designated prior to the study, correlations of busulfan levels with clinical outcome utilized studies following the fifth dose of busulfan. Table 2 presents the mean and standard deviation of the maximum busulfan level (Cmax) and area under the curve (AUC) following the fifth and 13th doses of busulfan. The Table 2 Busulfan levels of study patients 
Results
Busulfan levels
The influence of pretransplant factors on busulfan levels
There was no significant correlation of AUC (P = 0.2) or Cmax (P = 0.3) with diagnosis. However, patients who received no or minimal chemotherapy (one drug, eg hydroxyurea, or four or less cycles of a single standard regimen, eg CHOP) (n = 12) had lower AUC (P = 0.02) and Cmax (P = 0.03) following the fifth dose than patients who had received more extensive chemotherapy (n = 16) ( Figure 1 ). No significant correlation of extent of prior therapy with pretransplant liver function tests was detected (P Ͼ 0.2).
Association of busulfan levels with hepatic VOD and early death due to toxicity
The development of hepatic VOD (n = 10) was significantly associated with high AUC (P = 0.03) (Figure 2 ) but not with Cmax (P = 0.12). Early (within 6 months of transplantation) mortality (n = 8) was associated with high AUC (P = 0.06). 
Relapse, sustained survival, and delayed toxicity
Neither relapse (n = 4), late non-relapse death (n = 4), severe extensive chronic graft-versus-host disease (n = 4), obstructive bronchiolitis (n = 2), nor sustained event-free survival (n = 12) were significantly associated with AUC ( Figure 3 ) or Cmax (P Ͼ 0.2).
Discussion
The demonstration that busulfan levels predict acute toxicity, rejection and relapse has generated intense interest and attempts to dose-adjust busulfan to achieve 'targeted' plasma levels. The present study examines pretransplant factors which might influence busulfan levels and the Bone Marrow Transplantation association of busulfan levels with acute and delayed toxicity and long-term outcome.
Patients who had received more extensive treatment prior to transplant had significantly higher busulfan levels than patients who had received less treatment. This association has not been identified in other studies and requires confirmation. If verified, this association might permit adjustment of busulfan dose prior to initiation of conditioning regimens in both patients who are to undergo dose adjustment based on levels as well as those who will not. A significant correlation of underlying disease and busulfan levels was not detected, although such an effect has been reported by others. 17 Prior studies have demonstrated a higher incidence of acute toxicity, particularly hepatic VOD, among patients with high busulfan levels. [6] [7] [8] Hepatic VOD and early mortality were associated, in this study, with a high AUC following the fifth dose of busulfan.
Relapse of CML has been shown to be influenced by busulfan levels. 9 The present study did not identify a significant correlation between busulfan and relapse. The relatively small number of relapses and patient heterogeneity prevent meaningful conclusions.
Lastly, the long follow-up in this study permits study of long-term outcome. This was not significantly influenced by busulfan levels. Neither did the occurrence of delayed complications, eg chronic GVHD and bronchiolitis correlate with busulfan levels. Clearly, the power to detect such differences was limited by the number of patients. However, the contrast between the correlation of busulfan AUC with early mortality and the absence of correlation of busulfan AUC with delayed complications or disease-free survival is apparent in Figure 3 . These results should be regarded as preliminary. Studies with larger patient numbers are needed. Such studies would be important in determining the potential effectiveness of dose adjustment based on plasma levels in improving long-term survival and in defining optimal plasma levels for specific patient populations.
While many institutions dose-adjust busulfan based on plasma levels, and many investigators consider this 'standard' care, there is no direct evidence that this technique improves long-term outcome. In a given patient, lower busulfan levels might predispose to graft rejection or disease relapse, but would also result in less severe acute toxicity. While specific desired ranges may be sought, optimal levels probably vary substantially for different patients according to disease, stage, prior treatment, sensitivity to treatment, underlying organ function, donor source, degree of histocompatibility, and multiple other yet undefined variables.
'Desirable' levels in specific patients are not adequately defined at present. It would be useful if levels could be predicted by pre-transplant factors, eg disease and prior treatment. Busulfan dose adjustment based on plasma levels, intravenous busulfan, and other methods of improving busulfan-containing regimens promises to improve results. At present, however, these approaches require more thorough study in order to define their influence on long-term outcome, their most appropriate and optimal utilization, and to balance their considerable cost.
